News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
NewsBreak: Local News & Alerts Earnings
MediciNova (MNOV) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.06 loss and improving from a $0.07 loss a year ago. The company also exceeded revenue estimates, posting $0.46 million against a $0.15 million consensus, though its stock performance has lagged the S&P 500 this year. Analysts currently rate MNOV as …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
MediciNova (MNOV) reported a revenue increase to $0.5M in Q2 2026, primarily from Mayo ALS study services, while significantly narrowing its net loss to $2.3M. Research and development expenses decreased year-over-year, and the company's $25.4M in cash reserves are projected to fund operations until …
MediciNova Inc is projected to report a loss of 6 cents per share in its upcoming earnings. This information comes from a Refinitiv earnings preview. The full article provides more details on this financial forecast.
MediciNova, Inc. (MNOV) is expected to announce its Q2'26 earnings on August 14, with an estimated revenue of $75.00 thousand USD and an anticipated EPS of ($0.06) USD. The company's past reported revenues and EPS for previous quarters are also provided for comparison.
This article provides an earnings forecast for MediciNova Inc (MNOV), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on three analysts, the stock has a "Buy" trend with a significant upside space. The report also includes expected revenue and …
MediciNova (MNOV) is expected to release its Q2 2026 earnings after market close on Thursday, August 13th, with analysts projecting a loss of $0.06 per share and $75,000 in revenue. The company previously reported a loss of $0.05 per share, beating expectations, and matched …
This article displays the "Price to book forward" for MediciNova, Inc. (NASDAQ: MNOV) on TradingView. It provides financial data for the company, accessible through various features on the platform. The main content shows the period, value, and change metrics for this financial indicator.
This article provides a risk assessment for MediciNova Inc (MNOV), detailing its volatility, financial risk, and investment risk. The company's risk assessment score is 2.39, ranking 215 out of 385 in the Biotechnology & Medical Research industry, with a beta of 0.63 indicating less …
MediciNova Inc (MNOV) has a current financial score of 7.37, ranking 126 out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The analysis from TradingKey outlines several financial dimensions including Quality of Earnings (8.20), Operational …
This article provides a technical analysis of MediciNova Inc (MNOV), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. The current price momentum score is 3.44, suggesting suitability for range-bound swing trading between $1.24 and $1.45. …
The article concerns MediciNova Inc (MNOV) revenue breakdown by business segments and regional contributions. However, it states that the relevant data for FY2025, FY2025Q3, FY2025Q2, and FY2024 has not yet been disclosed by the company, making the provided regional breakdown effectively empty.
This article provides an overview of MediciNova Inc (MNOV)'s dividend and stock split history, noting that the company has distributed a total of $0.00 in dividends over the past five years. It presents real-time stock data including the current price, market cap, and a …
This article details the shareholder structure of MediciNova Inc (MNOV), listing its major shareholders, their proportional holdings, and the types of shareholders invested in the company. It also provides institutional shareholding trends over several quarters and recent shareholder activity, along with related ETF information.
This page provides the quarterly and annual income statements for MediciNova Inc (MNOV), detailing financial performance metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. It allows users to gain insights into the company's operational efficiency and profitability over …
MediciNova Inc's institutional confidence score is 3.00, placing it 192nd within the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.50%, a 42.46% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.39% of shares outstanding.
This article from TradingView provides a financial snapshot of MediciNova, Inc. (NASDAQ: MNOV), focusing on its enterprise value to EBIT forward. It indicates that the market was closed at the time of the view and there were no trades. The article is part of …
MediciNova Inc (MNOV) has a relatively healthy financial foundation and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Analysts predominantly rate the stock as "Buy," with a target price indicating significant upside. The company is in …
MediciNova Inc (MNOV) has a current valuation score of 7.33, placing it 248th out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is -5.53, which is a decline from its recent high but an increase from its recent low. …
This article provides the "Price to sales forward" data for MediciNova, Inc. (NASDAQ: MNOV), as presented on TradingView. It appears to be a financial data snippet, showing the value and change percentage for this specific metric over a certain period.
MediciNova (MNOV) stock continues to draw investor attention due to its late-stage neurology pipeline, despite an accumulated deficit of $540.8 million. The company reported a narrowed net loss of $19.0 million in 2024, down from $22.7 million in 2023, attributed to reduced operating expenses, …
MediciNova (MNOV) stock is trading steadily, reflecting investor focus on its clinical development pipeline despite recent revenue declines. The small-cap biotech's financial profile is shaped by its neurology, autoimmune, and respiratory asset development, with stable R&D spending backed by existing cash reserves. Key asset …
MediciNova (NASDAQ:MNOV) has successfully reached its target enrollment of 200 patients in the SEANOBI-ALS study for MN-166 (ibudilast) in treating amyotrophic lateral sclerosis. The study, funded by NIH under the ACT for ALS initiative, is expected to conclude patient follow-ups in early 2027, followed …
Three healthcare companies, Medicinova (MNOV), Legend Biotech (LEGN), and AngioDynamics (ANGO), have received bullish ratings from analysts. H.C. Wainwright analysts maintained Buy ratings for all three, with price targets of $10.00 for Medicinova, $65.00 for Legend Biotech, and $19.00 for AngioDynamics, suggesting significant upside …
MediciNova, Inc. announced the full enrollment of 200 patients in its NIH-funded SEANOBI-ALS study for MN-166 (ibudilast) as a treatment for Amyotrophic Lateral Sclerosis (ALS). This Expanded Access Program allows ALS patients ineligible for clinical trials to receive the investigational drug. Final patient follow-ups …
MediciNova (NASDAQ: MNOV) has achieved the enrollment target of 200 ALS patients in its NIH-funded SEANOBI-ALS Expanded Access Program, which evaluates MN-166 (ibudilast). This program allows ALS patients ineligible for randomized clinical trials to access the investigational drug. Final patient follow-ups are expected by …
MediciNova announced that it has achieved the target enrollment of 200 patients in its SEANOBI-ALS Expanded Access Program, which evaluates MN‑166 (ibudilast) for individuals with amyotrophic lateral sclerosis (ALS) who are not eligible for other clinical trials. This NIH-funded study reflects strong community engagement, …
Search by ticker symbol or company name and select a result to open its chart.